Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.

Oncology (Williston Park, N.Y.) - 15 Nov 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22229228

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.PMID 22229228Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.Semantic proximity Read ↗

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.Semantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutationsSemantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.